GLP-RT
COA published
A synthetic triple receptor agonist peptide studied in in-vitro GIP, GLP-1 and glucagon receptor binding research.
From$79.00Select size
AOD-9604
CAS221231-10-3MEASURED PURITY99.81%
A modified C-terminal fragment of human growth hormone (176-191) studied in structural and receptor research.
- Test methods
- HPLC-UV + LC-MS
- Purity target
- 99%+ verified
- Sizes available
- 1
- Availability
- Backordered
Select size
Quantity
1
Total
$49.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Batch J_0726-01-AOD10 · Certificate of Analysis available
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
✦ Research Notes
Background & literature
Origin
AOD-9604 is a synthetic fragment of human growth hormone corresponding to residues 177–191, the C-terminal region, with an added tyrosine. It came out of work by Frank Ng and colleagues at Monash University in Australia, who were investigating which structural domain of the growth-hormone molecule was responsible for which of its several activities. The 1993 paper on the synthetic C-terminal sequence is the founding publication; a 2000 study in J Mol Endocrinol examined the domain in Zucker rats.
What has been characterised
Characterised as a growth-hormone C-terminal fragment. The research premise is that this domain acts independently of the growth-hormone receptor and does not carry the receptor-mediated activity of the intact hormone — that separation of one domain from the whole is the reason the fragment was studied at all. A 2015 Drug Testing and Analysis paper examined its detection and in-vitro metabolism, work done in an anti-doping context. Rodent and in-vitro literature. Not FDA-approved for any use, and it is a compound under active regulatory attention; see lib/data.ts on why it is carried.
Sources
- 1.Biochem Mol Biol Int, 1993. PMID 8358331 — the founding publication on the synthetic C-terminal 177-191 sequence (title not reproduced here)
- 2.J Mol Endocrinol, 2000. PMID 11116208 — a structural-domain study in a rodent model (title not reproduced here)
- 3.“Detection and in vitro metabolism of AOD9604.” Drug Test Anal, 2015. PMID 25208511
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Batch releases & restocks
Know when the next batch is tested
We publish an independent certificate for every lot before it ships. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.
Related Compounds
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.